Abstract: Composition for use in the prevention and/or treatment of a mitochondrial dysfunction-related neurodegenerative diseases, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.

Abstract: Amino acid composition for use in the treatment of mucositis in patients suffering from head and neck cancer, undergoing radiation therapy and/or chemotherapy, the composition comprising an active agent, the active agent comprising the amino acids: glutamine, leucine, isoleucine, valine, lysine, threonine, histidine, phenylalanine, methionine, tryptophan, tyrosine, and cystine, wherein the glutamine:leucine weight ratio is in the range 4.3 to 5.3.

Abstract: Composition for use in the prevention and/or treatment of cancer in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, 5succinic acid, malic acid.

Abstract: Composition for use in the prevention and/or in the treatment of cardiotoxicity induced by at least one chemotherapeutic agent in a subject undergoing chemotherapy, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid. Said chemotherapeutic agent may be selected in the group consisting of anthracyclines, HER2/ErbB2 inhibitors, tyrosine-kinase inhibitors, vascular endothelial growth factor inhibitors, immune checkpoint inhibitors.

Abstract: Composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.

Abstract: Composition for use in the prevention and/or treatment of a mitochondrial dysfunction-related neurodegenerative diseases, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.

Abstract: Composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.

Abstract: Composition for use in the treatment of a central nervous system disease, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and the carboxylic acids citric acid, succinic acid, malic acid.

Abstract: Amino acid composition for use in the treatment of mucositis in patients suffering from head and neck cancer, undergoing radiation therapy and/or chemotherapy, the composition comprising an active agent, the active agent comprising the amino acids: glutamine, leucine, isoleucine, valine, lysine, threonine, histidine, phenylalanine, methionine, tryptophan, tyrosine, and cystine, wherein the glutamine:leucine weight ratio is in the range 4.3 to 5.3.

Abstract: Amino acid composition for use in the treatment of mucositis in patients suffering from head and neck cancer, undergoing radiation therapy and/or chemotherapy, the composition comprising an active agent, said active agent comprising the amino acids: glutamine, leucine, isoleucine, valine, lysine, threonine, histidine, phenylalanine, methionine, tryptophan, tyrosine, and cystine, wherein the glutamine:leucine weight ratio is comprised in the range 4.3 to 5.3.

Abstract: Composition for use in the prevention and/or treatment of a liver disease in a mammal, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and the carboxylic acids citric acid, succinic acid, malic acid.

Abstract: Amino acids compositions for use in the treatment of pain in patients who underwent elective arthroplasty.

Abstract: Composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.

Abstract: Composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.

Abstract: Amino acids compositions for use in the treatment of pain in patients who underwent elective arthroplasty.

Abstract: Amino acid composition for use in the treatment of mucositis in patients suffering from head and neck cancer, undergoing radiation therapy and/or chemotherapy, the composition comprising an active agent, said active agent comprising the amino acids: glutamine, leucine, isoleucine, valine, lysine, threonine, histidine, phenylalanine, methionine, tryptophan, tyrosine, and cystine, wherein the glutamine:leucine weight ratio is comprised in the range 4.3 to 5.3.

Abstract: Composition for use in the treatment of stroke, particularly in patients with dysphagia, the composition comprising an active agent, said active agent comprising the amino acids leucine, isoleucine, valine, lysine, threonine and at least one of histidine, phenylalanine, methionine, tryptophan, tyrosine, cystine. The composition further comprises one or more thickener agents in an amount between 10% and 50% by weight, more preferably between 20% and 30% by weight, with respect to the active agent weight.

Abstract: Composition for use in the treatment of stroke, particularly in patients with dysphagia, the composition comprising an active agent, said active agent comprising the amino acids leucine, isoleucine, valine, lysine, threonine and at least one of histidine, phenylalanine, methionine, tryptophan, tyrosine, cystine. The composition further comprises one or more thickener agents in an amount between 10% and 50% by weight, more preferably between 20% and 30% by weight, with respect to the active agent weight.

Abstract: The new pharmaceutical preparations contain hydrosoluble salts obtained through a reaction between Ketoprofen and Glucosamine and/or Proline and/or Hydroxyproline from 0.01 to 30% of the mass. Such preparations are useful for anti-inflammatory and analgesic treatment of joints and mucous membranes.

Abstract: Pharmaceutical composition containing nimesulide in a hydroalcoholic solution and a mixture of traditional vehicles and excipients for local use and application to the oral and rhinopharyngeal cavity for the treatment of inflammation of oral and rhinopharyngeal mucosae.